Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.710
+0.130 (5.04%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.
Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc.
| Country | United States |
| Founded | 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | David Mazzo |
Contact Details
Address: 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 United States | |
| Phone | 908 842 0100 |
| Website | lisata.com |
Stock Details
| Ticker Symbol | LSTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000320017 |
| CUSIP Number | 128058302 |
| ISIN Number | US1280583022 |
| Employer ID | 22-2343568 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Kristen K. Buck M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO and Principal Financial and Accounting Officer |
| Tariq Imam | Vice President of Business Development and Operations and Corporate Counsel |
| Gregory S. Berkin | Chief Information and Data Protection Officer |
| John D. Menditto | Vice President of Investor Relations and Corporate Communications |
| Gail Holler | Vice President of Human Resources |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 424B5 | Filing |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 27, 2024 | 8-K | Current Report |
| May 9, 2024 | EFFECT | Notice of Effectiveness |
| May 9, 2024 | 10-Q | Quarterly Report |